276°
Posted 20 hours ago

Café Stål Bellux Range 18/10 Stainless Steel Espresso Coffee Maker Classic Style Stovetop Italian Moka Pot Design, Hollow Cool Touch Handles, 10-Cup (580ml)

£9.9£99Clearance
ZTS2023's avatar
Shared by
ZTS2023
Joined in 2023
82
63

About this deal

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company. RCC is a cough that persists for more than eight weeks despite optimal treatment of any underlying conditions or where there is no identifiable underlying cause. 6 Cough hypersensitivity syndrome – excessive coughing, often in response to relatively innocuous stimuli – is now identified as the primary pathology in RCC. RCC is a frequent, yet often under-recognised, medical condition with significant physical, social, and psychological consequences on a patient’s quality of life. Two-thirds of patients are women averaging between 50-60 years old. 7 There are currently no approved treatments for this condition in the US or the EU. Meltzer et al. Prevalence and Burden of Chronic Cough in the United States. J of Allergy Clin Immunol Pract. 2021; 9:4037-44. Chamberlain et al. The impact of chronic cough: a cross-sectional European survey. Lung. 2015 Jun;193(3):401-8. BELLUS is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough.

Café Stål Bellux Range 18/10 Stainless Steel Espresso Coffee

Weather - October half term was our stay, we had a few days of it being changeable/overcast but mostly very warm, enough to sunbathe and swim, such a welcome sunshiny break. Currently in phase III clinical development with anticipated regulatory approval and launch in 2026GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2022, GSK’s Q4 Results for 2022 and any impacts of the COVID-19 pandemic. It is estimated that 28 million patients suffer from chronic cough, with 10 million patients globally and 6 million in the United States (US) and European Union (EU) suffering from RCC for over a year. 1 RCC is defined as a persistent cough for more than eight weeks that does not respond to treatment for an underlying condition or is otherwise unexplained. 2 RCC significantly impacts quality of life, with patients suffering from depression (53%), urinary incontinence (~50%), pain, rib fractures, social withdrawal, and loss of sleep. 3, 4 There are no approved medicines for RCC in the US and EU. Dicpinigaitis et al. Prevalence of Depressive Symptoms Among Patients With Chronic Cough. CHEST. 2006; 130 (6): 1839 – 43.

Adrian Flux Reviews | Read Customer Service Reviews of www Adrian Flux Reviews | Read Customer Service Reviews of www

GSK will account for the transaction as a business combination and expects it to be accretive to adjusted EPS in 2027, the expected first full year of camlipixant’s sales. Following the anticipated regulatory approval and launch of camlipixant in 2026, the acquisition is expected to be accretive to adjusted EPS from 2027 and has the potential to deliver significant sales through 2031 and beyond. Song et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015; 45: 1479–1481. Luke Miels, Chief Commercial Officer, GSK said: “Patients suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues. Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential. This proposed acquisition complements our portfolio of specialty medicines and builds on our expertise in respiratory therapies.” In December 2021, BELLUS announced positive data from the SOOTHE phase IIb trial, indicating that it met its primary endpoint for the 50 mg and 200 mg twice-daily doses. Based on these data, BELLUS initiated the CALM phase III development programme consisting of the CALM-1 and CALM-2 trials, with data anticipated in H2 2024 and 2025, respectively. BELLUS is also evaluating a QD (once-daily) formulation for camlipixant, which is currently in phase I.For over 50 years, GSK has led the way in developing medicines that advance the management of asthma and COPD, from introducing the world’s first selective short-acting beta agonist in 1969 to launching six treatments in five years to create today’s industry-leading respiratory portfolio. Food - We chose all inclusive, which was a great choice. We have teenagers that are usually hungry, and we liked regular tea/coffee/beer/fizzy drinks. The food was plentiful and delicious, with plenty of choice!! I wished they had pastel de nata (portugese custard tarts) for breakfast, that would have been a real treat! But then again they might be an expensive addition. They catered for all taste buds, I think. We all came away with happy bellies! And the pizza is the nicest I've ever eaten. Seriously.

Bellux Collection Cafetiere 3 Cup Stainless Steel - Lockhart

The acquisition of BELLUS is highly synergistic with GSK’s expertise in respiratory medicines and is further supported by GSK’s leading R&D, manufacturing, and commercialisation capabilities. Camlipixant is an investigational, twice-daily oral P2X3 receptor antagonist for the treatment of RCC, which is currently being evaluated in the CALM phase III clinical development programme. Given the need for novel and effective medicines for RCC, camlipixant has the potential to be a breakthrough in the treatment landscape. PJT Partners is acting as the exclusive financial advisor to GSK. Paul, Weiss, Rifkind, Wharton & Garrison LLP, and Stikeman Elliott LLP serve as legal counsel to GSK in connection with the transaction. Centerview Partners is acting as the exclusive financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP, and Davies Ward Phillips & Vineberg LLP serve as legal counsel to BELLUS. Pool - We saw the pool man clean regularly including a hoover like machine to clean the bottom (?). There were plenty of sunbeds and tables to pop your drinks on, umbrellas/parasols too. There is a sun terrace if you prefer to sit there and relax. Nice garden area too. Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough

Roberto Bellini, Chief Executive Officer of BELLUS, said: “This acquisition recognises the value of our highly selective P2X3 antagonist camlipixant and validates the hard work and dedication of all the BELLUS employees in advancing camlipixant to date. As a leader in respiratory research for over five decades, GSK shares our commitment to bettering the lives of individuals suffering from a persistent cough and is the ideal Company to rapidly bring camlipixant to the millions suffering from refractory chronic cough around the world.” Room - Hairdryer, shampoo, shower gel and handsoap included - which smelled lovely! Towels and bed linen was good quality. And rooms serviced daily, and well. Thank you to cleaners for their attention to detail and cleanliness.

Reviews (Albufeira, Algarve, Portugal) - Tripadvisor Updated 2023 Reviews (Albufeira, Algarve, Portugal) - Tripadvisor

There is no change to GSK’s full-year 2023 guidance or the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Asda Great Deal

Free UK shipping. 15 day free returns.
Community Updates
*So you can easily identify outgoing links on our site, we've marked them with an "*" symbol. Links on our site are monetised, but this never affects which deals get posted. Find more info in our FAQs and About Us page.
New Comment